Eisai slashes U.K. R&D jobs in 'global' restructuring

Japan's Eisai is slashing 20 R&D jobs and eliminating some 30 consultants contracts in the UK as part of a global R&D restructuring, according to a local spokesperson for the company. "That part of the business is being restructured globally, and jobs are at risk," the spokesperson told the Welwyn Hatfield Times. "We will support the employees whose jobs are being put at risk by this reorganization." More

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.